Due to the unique structure and prominent physicochemical properties, carbon nanotubes (CNTs) have been developed as promising nanocarriers to deliver drugs for cancer treatment. For improving the efficacy of drug nanocarrier and SERS traceability, the large-inner-diameter carbon nanotubes (LID-CNTs) with the hollow structure were employed to construct a novel drug delivery system. In brief, LID-CNTs are first to shorten through acid oxidation and sonication. Then, the gold/silver core-shell nanoparticles (Au@Ag NPs) were adsorbed onto the surfaces of LID-CNTs via electrostatic interactions, in which Au@Ag NPs were used as SERS-active structure. In such a nanohybrid, the model drug indole was loaded inside the hollow tunnels of LID-CNTs. Meanwhile, another drug, doxorubicin was loaded on the outer surface of LID-CNTs. Furthermore, indole and DOX can be triggered released by near-infrared (NIR) irradiation and acid pH conditions, respectively. Our experiment results demonstrate that this traceable LID-CNTs nanohybrids as dual-drug delivery systems exhibit significantly higher cell-killing effects, which have substantial potential for improving the therapeutic efficiency of cancer chemotherapy.
Dual-drug delivery systems designed for effective therapy is receiving much attention in cancer treatment, however, monitoring of the stimuli-responsive multi-drug release dynamics in living cells is still challenging. Here, a dual drug nanocarrier has been successfully synthesized using functionalized carbon nanotubes (CNTs). To obtain effective combination therapy, CNTs are used for loading dual drugs, that is, 6-thioguanine (6TG) and doxorubicin (DOX).By using label-free surface enhanced Raman scattering (SERS) and fluorescence techniques, the release dynamics of the loaded two kinds of drugs can be traced in living cells. In this nanocarrier, 6TG was conjugated to the surfaces of gold-silver core-shell nanoparticles (Au@Ag NPs). Release of 6TG can be triggered by glutathione (GSH). DOX was loaded onto CNTs surfaces via π–π stacking, which exhibits a pH-responsive release behavior. To investigate the intracellular traceable delivery performance of this nanocarrier, the dual drug loaded nanocarrier was incubated with living HeLa cells. Experimental results indicated that this dual drug nanocarrier can effectively enter into HeLa cells. And the release of 6TG and DOX were triggered by the substation of GSH and the acidic environment of lysosomes, respectively. By recording the real-time SERS and fluorescence signals of dual-drug inside HeLa cells, we can successfully monitor the dynamic process of intracellular drug release. Moreover, the combination of 6TG and DOX exhibited a synergistic effect to enhance the efficacy of cancer therapy. This kind of dual drug nanocarrier presents a new perspective for the design of smart multi-drug delivery systems for cancer therapy.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.